Treatment journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD

Edward L. Barnes,¹ Miguel Regueiro,² Shweta Shah,³ Harris A. Ahmad,³ Derek Gazis,⁴ Heather L. Morris,⁴ Julie M. Crawford,⁴ Megan Lutz,⁵ Marla C. Dubinsky,⁶ David T. Rubin,⁷ on behalf of the TARGET-IBD Investigators

¹UNC School of Medicine, Chapel Hill, NC, USA; ²Cleveland Clinic, Cleveland, OH, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁵University of Wisconsin, Madison, WI, USA; ⁴Target RWE, Durham, NC, USA; ⁴Target RWE, Durham, ⁴Target RWE, Durham, ⁴Target RWE, ⁴Target RWE, ⁴Targe ⁶Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁷University of Chicago Medicine, Chicago, IL, USA

Introduction

- Patients with moderate ulcerative colitis (UC) have a high prevalence of corticosterc (CS) use despite guidelines and known adverse effects¹⁻³
- The purpose of this project was to assess treatment patterns and associations of patie characteristics with the initiation of advanced therapy (AT) among patients with moderate UC

Methods

- TARGET-IBD (ClinicalTrials.gov identifier, NCT03251118) is a noninterventional, longitudinal cohort study of patients receiving care for inflammatory bowel disease (IBD) at 34 US academic or community gastroenterology sites
- Patients from TARGET-IBD were included if they met the following inclusion criteria
- Adults with UC diagnosed in 2012 or later (post biologic (bio) therapy launch)

- Receiving conventional therapy as a first treatment

- -No AT initiation (bio/Janus kinase inhibitor [JAKi]) within 30 days of starting conventional therapy
- Mayo Endoscopic Score (MES) = 2. When unavailable, a "pragmatic" MES definition used based on presence/severity of inflammation and ulcerations/erosions
- A Sankey diagram of the first 5 treatments from start of conventional therapy was generated
- Fine and Gray sub-distribution hazard regression models were used to estimate haza ratios (HRs) and 95% confidence intervals (CIs) for AT initiation




Figure 1. Study population

Presented at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting; October 20-25, 2023; Vancouver, BC, Canada

	Results			
roid	• Of 1695 patients with UC, 70 met the inclusion criteria (Figure 1)			e 1) Figure
ent	 Overall, patients were a median of 36 years old, male (51%), non-Hispanic White (73%), and had a median body mass index of 25.9 kg/m². The majority of patients were privately insured (79%) and were receiving care at academic sites (66%) 			
	 Conventional therapies were the most prevalent combination, with over 80% of patients receiving CS at some point during treatment (Figure 2) 			
2.	 A Sankey diagram of treatment journeys depicted high cycling between combinations of 5-ASA, IMM, and CS after initial treatment (Figure 3) 			
a:	 In the multivariable model (Figure 4), the likelihood of starting AT was significantly lower for Hispanic or non-White patients compared with non-Hispanic White patients (HR, 0.26; 95% CI, 0.09-0.77), and lower for patients aged 40-64 years at diagnosis compared with those aged 18-39 years (HR, 0.49; 95% CI, 0.23-1.06), and higher for those treated at academic sites compared with community sites (HR, 1.80; 			
า was	 95% CI, 0.92-3.53) The likelihood of starting AT was higher for patients with extensive disease compared with patients with proctitis, although this was not statistically significant (HR, 1.19; 95% CI, 0.54-2.63) (Figure 4) 			
	Among patients with moderate U high levels of cycling betweer 5-aminosalicylic acid, immunomo Figure 3. Treatment journey of patients with moderate UC			
			5-ASA + CS (57%)	5-ASA only (32%)
		5-ASA only (57%)		5-ASA + Bio/JAKi - CS only (5%)
			5-ASA + Bio/JAKi (5%)	5-ASA + CS + IMM 5-ASA + Bio/JAKi (
			CS only (7%)	Bio/JAKi only (3%)
		5-ASA + CS (21%)	5-ASA only (17%)	5-ASA + CS (13%)
		CS only (16%)		5-ASA + IMM (5%)
		co only (1070)	5-ASA + Bio/JAKi + CS (6%)	Bio/JAKi + CS (3%)

5-ASA + IMM (3%)

5-ASA + CS + IMM (3%)

IMM only (2%)

5-ASA + CS + IMM (3%)

5-ASA + Bio/JAKi + CS + IMM (2%)

IMM only (3%)

